# Tirzepatide Side Effects: What the Research Shows > Tirzepatide side effects from Phase 3 trials, safety meta-analyses, and pharmacovigilance data — the GI profile, gallbladder signal, lean-mass considerations, and the boxed thyroid warning, all cited. ## The short version Tirzepatide side effects fall into two broad groups: common, dose-related digestive effects that most people experience to some degree, and rarer but more serious signals that are monitored across the trial programme. The digestive effects — nausea, vomiting, constipation, diarrhea — are the most frequently reported category in both clinical trials and post-market pharmacovigilance data. They tend to peak during dose escalation and ease with continued use. The serious signals include a significantly elevated risk of gallbladder or biliary disease (confirmed in meta-analyses), a boxed warning for a thyroid C-cell tumor signal seen in rodents (not confirmed in humans), lean-muscle loss accompanying fat loss, and weight regain after stopping. Every figure on this page is cited to a peer-reviewed source. ## Gastrointestinal side effects — the dominant category Gastrointestinal adverse events are by far the most common tirzepatide side effects across the trial programme and real-world pharmacovigilance data. In SURMOUNT-1, nausea was reported by approximately 25% of participants at 5 mg, rising to about 30–33% at 15 mg; vomiting by approximately 8% at 5 mg and 11% at 15 mg; diarrhoea by approximately 16–20% across doses; and constipation by approximately 10–15% [4]. Events were predominantly mild to moderate and most frequent during dose escalation. A 2023 systematic review and meta-analysis by Mishra et al. characterised the GI side effect spectrum across the trial programme, documenting the dose-dependent and escalation-linked pattern [7]. A 2025 analysis by Safwan et al. using a meta-analytic approach across semaglutide and tirzepatide trials versus placebo confirmed the overall GI adverse-event risk at approximately 2.9-fold above placebo in a pooled obesity-trial cohort [6]. A 2026 bibliometric and pharmacovigilance analysis by Shen et al. used FAERS data to map the onset and clustering of GI events, finding a median time to onset of approximately 16 days and concentration in the first three months [8]. The 2025 FAERS disproportionality analysis by Almansour et al. confirmed gastrointestinal events as the dominant reported category and flagged incorrect dose administration as the single most frequent event type [19], reinforcing the importance of the stepwise escalation protocol. Clinically, the GI side effects of tirzepatide are the principal driver of discontinuation. The 2026 meta-analysis by Qazi et al. found discontinuation due to adverse events was approximately 32% higher with tirzepatide than with dulaglutide (a GLP-1 receptor agonist), driven substantially by GI intolerance [16]. ## Gallbladder and biliary disease — a confirmed signal Across multiple pooled analyses, tirzepatide is associated with a significantly elevated risk of gallbladder or biliary disease (the umbrella term covering gallstones, gallbladder inflammation, and bile duct disorders). Zeng et al. (2023) meta-analysed nine randomised controlled trials (9,871 participants) and found a significantly increased composite gallbladder-or-biliary-disease risk (relative risk 1.97, 95% CI 1.14–3.42) versus controls, while pancreatitis risk was not significantly elevated (relative risk 1.46, 95% CI 0.59–3.61) [14]. Gong et al. (2025) meta-analysed 12 trials and reported a comparable biliary disease signal (relative risk 1.52) and a cholelithiasis (gallstone) signal (relative risk 1.67) [18]. The class-level meta-analysis by Galli et al. (2025) found gallbladder disorders increased approximately 26% across GLP-1-based therapies [20]. The proposed mechanism is consistent with the observed effect: rapid weight loss is a well-established risk factor for gallstone formation (the cholesterol saturation of bile rises during rapid fat mobilisation). This mechanistic explanation suggests the gallbladder signal may be partly attributable to the weight loss itself rather than a direct drug toxicity. ## Boxed warning — thyroid C-cell tumours The FDA prescribing information carries a boxed warning (the most prominent level of drug-label warning) based on rodent data: in rats and mice, tirzepatide and structurally related incretins caused dose- and duration-dependent thyroid C-cell (parafollicular) tumours, including medullary thyroid carcinomas (MTC). Whether this signal translates to humans is not established, and the relevance of the rodent data to human risk is uncertain [11, 12]. Because of this unconfirmed but unexcluded signal, the label states that tirzepatide is contraindicated in people with: - A personal or family history of medullary thyroid carcinoma - Multiple Endocrine Neoplasia syndrome type 2 (MEN-2) People taking tirzepatide are advised to report a neck lump, hoarseness, difficulty swallowing, or shortness of breath to a healthcare provider, as these could be symptoms of thyroid cancer. The contraindication is a precautionary measure grounded in animal data. ## Lean-mass and skeletal-muscle loss Weight loss achieved with tirzepatide — as with other potent weight-reduction interventions — includes a fraction of lean (muscle) mass alongside fat mass. Look et al. (2025) in a SURMOUNT-1 DXA (dual-energy X-ray absorptiometry — a body-composition imaging method) substudy found approximately 25% of the weight lost was lean mass and approximately 75% was fat mass [24]. Batsis et al. (2026), in a broader systematic review of incretin and non-pharmacological weight-loss interventions, put the median muscle-attributable share of weight loss near 28% across incretin trials, characterising the lean-mass loss as comparable to a decade or more of the age-related muscle decline and recommending resistance exercise to attenuate the effect [25]. Locatelli et al. (2024) in a Diabetes Care review examined the role of resistance exercise in preserving muscle during incretin-based weight loss [26]. The functional significance of the observed lean-mass loss — whether it translates to measurable losses in physical performance, grip strength, or functional independence — is still being assessed across the trial programme. ## Other monitored signals **Pancreatitis** — Label-monitored and captured in pharmacovigilance data, but the dedicated meta-analysis (Zeng et al., 2023) found no statistically significant increase in randomised trials. A propensity-matched cohort study by Nassar et al. (2024) found a lower five-year recurrence rate among tirzepatide users with a history of pancreatitis, suggesting the population risk may be complex [22]. Severe, persistent abdominal pain should prompt evaluation. **Hair loss (telogen effluvium)** — A 2025 pharmacovigilance review in Cureus documented hair thinning and shedding in a subset of users, attributing it to telogen effluvium — the temporary diffuse shedding triggered by rapid weight loss and nutrient deficit rather than direct drug toxicity. Clinical trial data recorded hair loss in approximately 4–5% of tirzepatide participants versus approximately 1% with placebo [32]. Most cases self-resolve once weight stabilises. **Weight regain after stopping** — Randomised withdrawal data (SURMOUNT-4, Aronne et al., 2024) confirmed that participants switched to placebo after 36 weeks of tirzepatide regained substantial weight, while those continuing to tirzepatide kept losing [29]. Horn et al. (2026) documented worsening of cardiometabolic markers alongside the weight regain [31]. **Hypoglycaemia with insulin or sulfonylureas** — Standalone hypoglycaemia risk is low because tirzepatide stimulates insulin in a glucose-dependent manner. When added to insulin or a sulfonylurea (a class of diabetes medicines that force insulin release independent of glucose), the risk increases; the FDA label advises dose reduction of the concomitant agent [11, 23]. **Dehydration and acute kidney injury from severe GI losses** — Severe vomiting, diarrhoea, and reduced fluid intake during treatment can cause volume depletion, particularly in people on diuretics, ACE inhibitors, or ARBs. Large randomised datasets do not show a population-level increase in acute kidney injury; the risk is tied to severity of GI side effects rather than a direct drug effect [15, 6]. See the full [Tirzepatide research](/research) and [Tirzepatide references](/references) pages for the complete evidence record. --- A newsroom reading of the tirzepatide safety record — the 2024–2025 trials and meta-analyses set down and cited, with no clinic, no prescriber, and no verdict on any individual's risk.